Navigation Links
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology

Results from Phase II Trial of DU-176b in Atrial Fibrillation Included in Scientific Program

EDISON, N.J., Dec. 2 /PRNewswire/ -- Daiichi Sankyo, Inc. (TSE: 4568), today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), to be held December 6 - 9, 2008, in San Francisco. The data accepted for the ASH meeting are part of the clinical development of DU-176b, an oral Factor Xa inhibitor being investigated to prevent the formation of blood clots. Information on the studies to be presented at the meeting is as follows:

  • Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation (Abstract 33), by Jeffrey Weitz MD, FACP, FRCP, Henderson Research Centre, Hamilton, Ontario, Stuart J. Connolly, MD, FRCPC, Division of Cardiology, McMaster University, Hamilton, Ontario, Satoshi Kunitada, Daiichi Sankyo Pharma Development, Edison, New Jersey, James Jin, Daiichi Sankyo Pharma Development, Edison, New Jersey, Indravadan Patel, Daiichi Sankyo Pharma Development, Edison, New Jersey.This will be an oral presentation on Sunday, December 7, 2008.
  • Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (Abstract 34), by Takashi Fuji, MD, Department of Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka, Japan, Satoru Fujita, MD, Department of Orthopaedic Surgery, Takarazuka Daiichi Hospital, Hyogo, Japan, Shintaro Tachibana, MD, Department of Orthopaedic Surgery, Toranomon Hospital, Tokyo, Japan and Yohko Kawai, MD, Sanno Hospital, Tokyo, Japan. This will be an oral presentation on Sunday, December 7, 2008.
  • Study of Coagulation and Platelets Response in an Open Label Randomized Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU-176b) in 4 Groups of Elderly Healthy Subjects (Abstract 3026), Professor Michel Meyer Samama, Biomnis, Ivry-sur-Seine cedex, France, Satoshi Kunitada, Daiichi Sankyo Pharma Development, Edison, New Jersey, A. Oursin, Biomnis, Ivry-sur-Seine cedex, France, Francois Depasse, Biomnis, Ivry-sur-Seine cedex, France and Nazneen Haque, Daiichi Sankyo Development Ltd., Gerald Cross, Buckinghamshire, United Kingdom. This will be a poster presentation on Monday, December 8, 2008.

To arrange an interview with Francis Plat, MD, vice president, clinical development at Daiichi Sankyo Pharma Development, or Jeffrey Weitz, MD, FACP, FRCP, Professor of Medicine and Biochemistry, McMaster University and Director, Henderson Research Centre, Hamilton, Ontario at the 2008 ASH Meeting in San Francisco, please contact Kim Wix, Daiichi Sankyo, at 973-695-8338 (office) 908-656-5447 (mobile) or Catherine Falcetti, MS&L, at 212-468-4337 (office) or 646-246-1843 (mobile).

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

About Daiichi Sankyo, Inc.

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. Equally important to the company is the discovery of new medicines in the areas of cancer, infectious diseases, bone and joint diseases, and immune disorders. For more information, visit

Daiichi Sankyo, Inc., a subsidiary of the global research-based pharmaceutical company, is based in Parsippany, NJ.

    For more information, please contact:

    Kim Wix
    Daiichi Sankyo (U.S.A.)
    973-695-8338 (office)
    908-656-5447 (cell)

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
2. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
3. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
4. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
5. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
6. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
7. In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia
8. EMS Magazine Announces Top Innovation Awards for 2008
9. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Transition Therapeutics Announces Dates for Upcoming Corporate Events
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology: